Search
Sprifermin
go.drugbank.com/drugs/DB12616InvestigationalSprifermin has been used in trials studying the treatment of Osteoarthritis, Knee and Cartilage Injury of Knee.
BMS-184476
go.drugbank.com/drugs/DB12633InvestigationalBMS-184476 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
NSI-189
go.drugbank.com/drugs/DB16230InvestigationalNSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).
NKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalChimeric antigen receptors (CARs) are artificial receptors consisting of an antibody-derived antigen binding domain and transmembrane and signaling domains from T-cell receptor signalling moieties.
Onametostat
go.drugbank.com/drugs/DB21480InvestigationalThe usage of the INN stem '-metostat' in the name indicates that Onametostat is a histone N-methyltransferase inhibitor. … Onametostat is under investigation in clinical trial NCT06788509 (A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring).
Nifurizone
go.drugbank.com/drugs/DB19694ExperimentalThe usage of the INN stem '-zone' in the name indicates that Nifurizone is a anti-inflammatory analgesic, phenylbutazone derivative. … The usage of the INN stem 'nifur-' in the name indicates that Nifurizone is a 5-nitrofuran derivative. Nifurizone has a monoisotopic molecular weight of 307.09 Da.
Nifurethazone
go.drugbank.com/drugs/DB20112ExperimentalThe usage of the INN stem '-azone' in the name indicates that Nifurethazone is a anti-inflammatory analgesic, phenylbutazone derivative. … The usage of the INN stem 'nifur-' in the name indicates that Nifurethazone is a 5-nitrofuran derivative. Nifurethazone has a monoisotopic molecular weight of 269.11 Da.
Casdatifan
go.drugbank.com/drugs/DB21701InvestigationalThe usage of the INN stem '-tifan' in the name indicates that Casdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor. … Casdatifan is under investigation in clinical trial NCT07000149 (A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC)
AGS-005
go.drugbank.com/drugs/DB05741ExperimentalAGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.